Hauptseite > Publikationsdatenbank > Semisynthetic Analogs of the Antibiotic Fidaxomicin—Design, Synthesis, and Biological Evaluation > print

001     885797
005     20210130010520.0
024 7 _ |a 10.1021/acsmedchemlett.0c00381
|2 doi
024 7 _ |a 2128/26511
|2 Handle
024 7 _ |a altmetric:92427450
|2 altmetric
024 7 _ |a 33329763
|2 pmid
024 7 _ |a WOS:000599586900006
|2 WOS
037 _ _ |a FZJ-2020-04094
082 _ _ |a 610
100 1 _ |a Dorst, Andrea
|0 P:(DE-HGF)0
|b 0
245 _ _ |a Semisynthetic Analogs of the Antibiotic Fidaxomicin—Design, Synthesis, and Biological Evaluation
260 _ _ |a Washington, DC
|c 2020
|b ACS
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1607700576_19866
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a The glycoslated macrocyclic antibiotic fidaxomicin (1, tiacumicin B, lipiarmycin A3) displays good to excellent activity against Gram-positive bacteria and was approved for the treatment of Clostridium difficile infections (CDI). Among the main limitations for this compound, its low water solubility impacts further clinical uses. We report on the synthesis of new fidaxomicin derivatives based on structural design and utilizing an operationally simple one-step protecting group-free preparative approach from the natural product. An increase in solubility of up to 25-fold with largely retained activity was observed. Furthermore, hybrid antibiotics were prepared that show improved antibiotic activities.
536 _ _ |a 511 - Computational Science and Mathematical Methods (POF3-511)
|0 G:(DE-HGF)POF3-511
|c POF3-511
|f POF III
|x 0
536 _ _ |a Forschergruppe Gohlke (hkf7_20200501)
|0 G:(DE-Juel1)hkf7_20200501
|c hkf7_20200501
|f Forschergruppe Gohlke
|x 1
588 _ _ |a Dataset connected to CrossRef
700 1 _ |a Berg, Regina
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Gertzen, Christoph G. W.
|0 P:(DE-Juel1)174133
|b 2
700 1 _ |a Schäfle, Daniel
|0 P:(DE-HGF)0
|b 3
700 1 _ |a Zerbe, Katja
|0 P:(DE-HGF)0
|b 4
700 1 _ |a Gwerder, Myriam
|0 P:(DE-HGF)0
|b 5
700 1 _ |a Schnell, Simon D.
|0 P:(DE-HGF)0
|b 6
700 1 _ |a Sander, Peter
|0 P:(DE-HGF)0
|b 7
700 1 _ |a Gohlke, Holger
|0 P:(DE-Juel1)172663
|b 8
700 1 _ |a Gademann, Karl
|0 0000-0003-3053-0689
|b 9
|e Corresponding author
773 _ _ |a 10.1021/acsmedchemlett.0c00381
|g p. acsmedchemlett.0c00381
|0 PERI:(DE-600)2532386-6
|n 12
|p 2414–2420
|t ACS medicinal chemistry letters
|v 11
|y 2020
|x 1948-5875
856 4 _ |y OpenAccess
|u https://juser.fz-juelich.de/record/885797/files/ACS_ML_revised.pdf
856 4 _ |y OpenAccess
|u https://juser.fz-juelich.de/record/885797/files/acsmedchemlett.0c00381.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://juser.fz-juelich.de/record/885797/files/ACS_ML_revised.pdf?subformat=pdfa
909 C O |o oai:juser.fz-juelich.de:885797
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 2
|6 P:(DE-Juel1)174133
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 8
|6 P:(DE-Juel1)172663
913 1 _ |a DE-HGF
|b Key Technologies
|1 G:(DE-HGF)POF3-510
|0 G:(DE-HGF)POF3-511
|2 G:(DE-HGF)POF3-500
|v Computational Science and Mathematical Methods
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|l Supercomputing & Big Data
914 1 _ |y 2020
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2020-01-03
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2020-01-03
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2020-01-03
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2020-01-03
915 _ _ |a Creative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0
|0 LIC:(DE-HGF)CCBYNCND4
|2 HGFVOC
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ACS MED CHEM LETT : 2018
|d 2020-01-03
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2020-01-03
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
|d 2020-01-03
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2020-01-03
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1200
|2 StatID
|b Chemical Reactions
|d 2020-01-03
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
|d 2020-01-03
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2020-01-03
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2020-01-03
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2020-01-03
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2020-01-03
920 _ _ |l yes
920 1 _ |0 I:(DE-Juel1)JSC-20090406
|k JSC
|l Jülich Supercomputing Center
|x 0
920 1 _ |0 I:(DE-Juel1)NIC-20090406
|k NIC
|l John von Neumann - Institut für Computing
|x 1
920 1 _ |0 I:(DE-Juel1)IBI-7-20200312
|k IBI-7
|l Strukturbiochemie
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-Juel1)JSC-20090406
980 _ _ |a I:(DE-Juel1)NIC-20090406
980 _ _ |a I:(DE-Juel1)IBI-7-20200312
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21